|
Susan F. Slovin, M.D., Ph.D. is a board certified oncologist with clinical
expertise in immunotherapy of prostate cancer as well as clinical trial design
with particular emphasis in patients with rising Prostatic Specific Antigen
following failure of primary therapy. She is currently an Assistant Member on
the Genitourinary Oncology Service n the Department of Medicine at Memorial
Sloan-Kettering Cancer Center, New York, NY and is an Assistant Professor of
Medicine at New York Hospital-Weill Medical College, New York, New York.
Dr.
Slovin is the ASCO representative to the Board of the National Prostate Cancer
Coalition. She has research expertise in clinical immunology as well as
genitourinary malignancies and is in charge of the vaccine therapy program for
prostate cancer. Dr. Slovin has co-authored over 100 scientific articles and won
the Public Health Service National Research Award.
Previously, Dr. Slovin was a Visiting Investigator at Memorial
Sloan-Kettering and there she developed an interest in T-cell recognition
killing. She was also the Adjunct Research Assistant Professor of Medicine,
Division of Medical Oncology, and Adjunct Research Assistant Professor of
Microbiology at Thomas Jefferson University School of Medicine in Philadelphia,
PA. While at Thomas Jefferson University, she was the first to identify the role
of HLA-A2 in T-cell recognition and killing of solid tumors.
Dr. Slovin has a Medical Doctorate from Jefferson Medical College in
Philadelphia, PA and completed her residency at Mount Sinai Medical Center in
New York, NY. She also has a Ph.D. from Columbia University Graduate School of
Arts and Sciences, New York, NY. She was a fellow in Hematology and Oncology at
Memorial Sloan-Kettering Cancer Center prior to becoming a faculty member there.
She was also a fellow in clinical oncology at Scripps Clinic & Research
Foundation, La Jolla, CA. |
